
    
      This is a non-interventional, observational, open-label, multi-country, multicenter
      post-marketing study in which Zemplar (paricalcitol) is prescribed in the usual manner in
      accordance with the terms of the local marketing authorization. Follow up visits will occur
      1, 3, 6, 9, and 12 months after screening.
    
  